Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
264.2 INR | +2.94% | +6.21% | +5.81% |
15.03. | Eris Lifesciences erwirbt das indische Formulierungsgeschäft von Biocon Biologics für 12,42 Milliarden INR | MT |
15.03. | Biocons CFO tritt zurück | MT |
Kurzporträt
Mitarbeiterzahl: 16 545
Umsatz nach Geschäftsbereich
INR in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
Biosimilars
49,8
%
| 34 301 | 41,9 % | 55 599 | 49,8 % | +62.09% |
Research
28,1
%
| 25 119 | 30,7 % | 31 392 | 28,1 % | +24.97% |
Generics
22,0
%
| 21 910 | 26,8 % | 24 559 | 22,0 % | +12.09% |
Novels
0,2
%
| 510 | 0,6 % | 192 | 0,2 % | -62.35% |
Umsatz je Region
INR in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
Rest of the World
37,4
%
| 21 468 | 26,2 % | 41 791 | 37,4 % | +94.67% |
United States
37,1
%
| 29 946 | 36,6 % | 41 430 | 37,1 % | +38.35% |
India
15,0
%
| 13 563 | 16,6 % | 16 737 | 15,0 % | +23.40% |
Ireland
10,5
%
| 16 863 | 20,6 % | 11 784 | 10,5 % | -30.12% |
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Siddharth Mittal
CEO | Chief Executive Officer | 46 | 01.05.13 |
Peter Bains
CEO | Chief Executive Officer | 65 | 12.12.22 |
Chairman | 71 | 29.11.78 | |
Chief Tech/Sci/R&D Officer | - | - | |
Mayank Verma
CMP | Compliance Officer | - | 01.01.12 |
Shreehas Tambe
PRN | Corporate Officer/Principal | - | 01.07.97 |
Corporate Officer/Principal | - | - | |
Akhilesh Nand
LAW | General Counsel | - | 03.02.18 |
Amitava Saha
HRO | Human Resources Officer | 54 | 01.12.13 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Chairman | 71 | 29.11.78 | |
Director/Board Member | 69 | 01.01.00 | |
Director/Board Member | 59 | 27.07.18 | |
Director/Board Member | 76 | 27.04.16 | |
Peter Bains
CEO | Chief Executive Officer | 65 | 12.12.22 |
Naina Lal Kidwai
BRD | Director/Board Member | 66 | 28.04.22 |
Eric Mazumdar
BRD | Director/Board Member | 31 | 01.11.21 |
Nicholas Haggar
BRD | Director/Board Member | 58 | 01.09.23 |
Siddharth Mittal
CEO | Chief Executive Officer | 46 | 01.05.13 |
Director/Board Member | - | 26.07.23 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 1 196 590 319 | 446 005 810 ( 37,27 %) | 0 | 37,27 % |
Unternehmensbesitz
Name | Aktien | % | Bewertung |
---|---|---|---|
219 185 608 | 54,52% | 1 867 338 636 $ | |
EQUILLIUM, INC. 10,54% | 2 316 134 | 10,54% | 5 767 174 $ |
Unternehmenskontakt
Biocon Ltd.
20th KM, Hosur Road Electronics City
560100, Bangalore
+91 80 2808 2808
http://www.biocon.comKonzerngesellschaften
Name | Kategorie und Branche |
---|---|
Miscellaneous Commercial Services
| |
Biocon Research Ltd.
Biocon Research Ltd. Pharmaceuticals: MajorHealth Technology Part of Biocon Ltd., Biocon Research Ltd. is an Indian company that develops and sells biotechnology products. The private company is based in Bangalore, India. |
Pharmaceuticals: Major
|
Biocon Sdn. Bhd.
Biocon Sdn. Bhd. Pharmaceuticals: MajorHealth Technology Biocon Sdn. Bhd. manufactures insulin products. It provides research and development activities of biopharmaceutical products. The company was founded in 2010 and is headquartered in Nusajaya, Malaysia. |
Pharmaceuticals: Major
|
Biocon Biologics Ltd. (India)
Biocon Biologics Ltd. (India) Pharmaceuticals: MajorHealth Technology Biocon Biologics India Ltd. operates as a biotech company. It develops treatments for chronicle diseases. The company is headquartered in Bengaluru, India. |
Pharmaceuticals: Major
|
Biocon Pharma Ltd.
Biocon Pharma Ltd. Pharmaceuticals: MajorHealth Technology Part of Biocon Ltd., Biocon Pharma Ltd. is an Indian pharmaceutical company that manufactures pharmaceutical preparations. The private company is based in Bangalore, India. |
Pharmaceuticals: Major
|
Biofusion Therapeutics Ltd.
Biofusion Therapeutics Ltd. BiotechnologyHealth Technology Biofusion Therapeutics Ltd. is an Indian company that focuses on researching and developing new molecules for targeted immuno-oncology therapy. The private company is based in Bangalore, India. |
Biotechnology
|
Biocon Biologics Uk Ltd.
Biocon Biologics Uk Ltd. Miscellaneous Commercial ServicesCommercial Services Biocon Biologics UK Ltd. is a biopharmaceutical company founded in 2016. The private company is based in London, UK. The British company is focused on finding new and affordable ways to treat diabetes, cancer, and autoimmune diseases. Biocon develops affordable biosimilars, generic formulations, and complex APIs. The company's work in novel biologics and novel targets in large molecules has significant results in diabetes, oncology, and immunology. The company provides access to share information, news, press releases, company statements, media stories, factsheet, leadership profile, reports, video, and image gallery. Syngene, a division of Biocon, is divided into four divisions - drug discovery services, drug development services, manufacturing services, and dedicated R&D centers. |
Miscellaneous Commercial Services
|
Sektor
Umsatz nach Geschäftsbereich
Umsatz je Region
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
+5.81% | 3.68 Mrd. | |
+3.33% | 108 Mrd. | |
+9.85% | 104 Mrd. | |
+6.43% | 23.66 Mrd. | |
-11.69% | 22.1 Mrd. | |
-3.29% | 19.71 Mrd. | |
-35.36% | 18.2 Mrd. | |
-13.21% | 16.19 Mrd. | |
+5.01% | 13.72 Mrd. | |
+34.86% | 12.22 Mrd. |
- Börse
- Aktien
- Aktie Biocon Limited - NSE India S.E.
- Unternehmen Biocon Limited